Page 3 - Pharmaengine Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Headed by the successful biotech entrepreneur Grace Yeh, Onward Therapeutics pursues a buy and build strategy with the goal to identify and develop innovative medicines for the treatment of cancer. The company which was founded in 2020 and is based at Biopôle has now closed the first contracts with two biotech start-ups. Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder, President and Chief Executive Of...

(1) Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels An injection procedure-related dose-limiting toxicity of urinary tract infection was observed in the study, however there were no observed adverse events or severe adverse events associated with NBTXR3 More than 70% of patients showed objective tumor response after concurrent...

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021 The ...